8-K: Cassava Sciences Reports Stable Cognition in Mild Alzheimer's Patients with Simufilam Over Two Years

Cassava Sciences announced that patients with mild Alzheimer's disease who continuously received simufilam for two years showed no decline in cognitive scores, while those with non-continuous treatment experienced a slight decline.

Summary

• Cassava Sciences released top-line results from a two-year clinical safety study of simufilam, an oral drug for Alzheimer's disease.
• The study included over 200 patients with mild to moderate Alzheimer's and had open-label treatment phases and a randomized, placebo-controlled withdrawal phase.
• Patients with mild Alzheimer's who received simufilam continuously for two years (n=47) showed no decline in ADAS-Cog scores, with an average change of 0.07 points.
• Mild Alzheimer's patients who received simufilam non-continuously (n=40) declined by an average of 1.04 points on the ADAS-Cog scale.
• Non-continuous treatment involved one year on the drug, six months on placebo, and six months back on the drug.
• Patients with moderate Alzheimer's who received simufilam continuously for two years (n=32) declined by 11.05 points on the ADAS-Cog scale.
• The largest difference between continuous and non-continuous treatment groups in mild patients was observed at the end of the 6-month placebo-controlled withdrawal phase.
• The study was a safety study with a pre-specified exploratory efficacy endpoint of mean change in ADAS-Cog11 scores.
• The most common adverse events were Covid-19 and urinary tract infections, with 33 occurrences each, and there were no drug-related serious adverse events.
• The company is currently conducting two Phase 3 clinical studies of simufilam, with top-line results expected by the end of 2024 and mid-2025.

Sentiment

Score: 7

Explanation: The document presents positive results for simufilam in mild Alzheimer's patients, but also acknowledges limitations and risks. The overall tone is cautiously optimistic, with a focus on the potential of the drug while recognizing the need for further research.

Positives

• Simufilam showed a potential benefit in maintaining cognitive stability in patients with mild Alzheimer's disease when administered continuously for two years.
• The drug appeared safe and well-tolerated, with no drug-related serious adverse events reported.
• The study results suggest that early treatment with simufilam may be beneficial for patients with mild Alzheimer's.
• The company has two fully enrolled Phase 3 clinical studies underway, with results expected in the near future.

Negatives

• Patients with moderate Alzheimer's experienced a significant decline in cognitive scores despite continuous treatment with simufilam.
• The study was an open-label design, which may introduce bias and limit the interpretation of the results.
• The study had a limited size, which may not fully distinguish between drug effects and random variation.
• The study results do not constitute regulatory evidence of safety or efficacy for simufilam in Alzheimer's disease dementia.

Risks

• The open-label design and limited size of the study may introduce clinical or statistical bias.
• The study results may not fully distinguish between drug effects and random variation.
• There is a risk that the final data may change from the top-line data reported.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for simufilam.
• The company acknowledges that different methods of statistical analysis may lead to different numerical results.
• The company does not know how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam.

Future Outlook

Cassava Sciences expects to report top-line results from two ongoing Phase 3 clinical studies of simufilam by the end of 2024 and mid-2025, respectively. The company also plans to present the two-year clinical safety study data at a science forum.

Management Comments

• Remi Barbier, President & CEO, stated that they are fighting Alzheimer's disease by testing simufilam, a new type of drug with a different mechanism of action from monoclonal antibody treatments.
• Remi Barbier also noted that stable ADAS-Cog scores over 2 years is a desirable clinical outcome in Alzheimer's and that their data in mild patients may emphasize the importance of treating patients early in the disease.

Industry Context

This announcement is significant in the context of the ongoing search for effective treatments for Alzheimer's disease, a major global health challenge. The results suggest a potential benefit of simufilam in maintaining cognitive stability in mild Alzheimer's patients, which contrasts with the typical progression of the disease. The company is differentiating itself from monoclonal antibody treatments by using a different mechanism of action.

Comparison to Industry Standards

• The science literature suggests that patients with mild Alzheimer's decline by a group average of approximately 3 points per year on the ADAS-Cog scale, which makes the 0.07 point change in the continuous treatment group a notable result.
• Other companies such as Biogen and Eisai have developed monoclonal antibody treatments for Alzheimer's, which have shown some efficacy in slowing cognitive decline, but also have potential side effects.
• The results of this study suggest that simufilam may offer a different approach to treating Alzheimer's, potentially targeting the underlying pathology of the disease.

Stakeholder Impact

• Shareholders may view the results positively, as they suggest potential for simufilam to be an effective treatment for Alzheimer's disease.
• Patients with Alzheimer's and their families may be encouraged by the potential of simufilam to slow or halt cognitive decline.
• Employees of Cassava Sciences may be motivated by the positive results and the progress of the clinical trials.
• The scientific community may be interested in the results and the unique mechanism of action of simufilam.

Next Steps

• The company expects to report top-line results from two ongoing Phase 3 clinical studies of simufilam by the end of 2024 and mid-2025.
• The company plans to present the two-year clinical safety study data at a science forum.

Key Dates

Keywords

Simufilam, Alzheimer's disease, Cognitive decline, Clinical trial, ADAS-Cog, Neurodegenerative disease, Biotechnology, Phase 3, Drug development, Open-label study